Warfarin Pharmacogenetics: To Genotype or Not to Genotype, That Is the Question

被引：22
|
作者：
Cavallari, L. H. [1 ]
Nutescu, E. A. [1 ,2 ,3 ]
机构：
[1] Univ Florida, Dept Pharmacotherapy & Translat Res, Gainesville, FL 32610 USA
[2] Univ Illinois, Dept Pharm Syst Outcomes & Policy, Chicago, IL USA
[3] Univ Illinois, Ctr Pharmacoepidemiol & Pharmacoecon Res, Chicago, IL USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2014年 / 96卷 / 01期
关键词：
D O I：
10.1038/clpt.2014.78
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Genotype is well recognized to influence the dose of warfarin necessary for therapeutic anticoagulation. Recent randomized controlled trials evaluating the clinical utility of genotype-guided warfarin dosing have produced varying results. We review the design and results of the recent clinical trials, assess the impact of their findings on warfarin dosing, and examine unanswered questions related to clinical implementation of warfarin pharmacogenetics.
引用
收藏
页码：22 / 24
页数：3
相关论文
共 50 条
  • [21] A Randomized Trial of Genotype-Guided Dosing of Warfarin
    Pirmohamed, Munir
    Burnside, Girvan
    Eriksson, Niclas
    Jorgensen, Andrea L.
    Toh, Cheng Hock
    Nicholson, Toby
    Kesteven, Patrick
    Christersson, Christina
    Wahlstrom, Bengt
    Stafberg, Christina
    Zhang, J. Eunice
    Leathart, Julian B.
    Kohnke, Hugo
    Maitland-van der Zee, Anke H.
    Williamson, Paula R.
    Daly, Ann K.
    Avery, Peter
    Kamali, Farhad
    Wadelius, Mia
    NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (24): : 2294 - 2303
  • [22] Genotype-guided warfarin therapy: current status
    Tavares, Leticia C.
    Marcatto, Leiliane R.
    Santos, Paulo C. J. L.
    PHARMACOGENOMICS, 2018, 19 (07) : 667 - 685
  • [23] Genotype and risk of major bleeding during warfarin treatment
    Kawai, Vivian K.
    Cunningham, Andrew
    Vear, Susan I.
    Van Driest, Sara L.
    Oginni, Abimbola
    Xu, Hua
    Jiang, Min
    Li, Chun
    Denny, Joshua C.
    Shaffer, Christian
    Bowton, Erica
    Gage, Brian F.
    Ray, Wayne A.
    Roden, Dan M.
    Stein, C. Michael
    PHARMACOGENOMICS, 2014, 15 (16) : 1973 - 1983
  • [24] Apolipoprotein E genotype alters warfarin dose requirements
    Kimmel, Stephen E.
    Christie, Jason
    Chen, Zhen
    Price, Maureen
    Brensinger, Colleen
    Newcomb, Craig
    Kealey, Carmel
    Whitehead, Alexander S.
    CIRCULATION, 2006, 114 (18) : 888 - 888
  • [25] Warfarin pharmacogenetics
    Johnson, Julie A.
    Cavallari, Larisa H.
    TRENDS IN CARDIOVASCULAR MEDICINE, 2015, 25 (01) : 33 - 41
  • [26] Genotype and " genotype "
    Schuchert, C
    SCIENCE, 1912, 35 (01) : 304 - 304
  • [27] Pharmacogenetics of indirect anticoagulants: Value of genotype for improvement of efficacy and safety of therapy
    Sytchev, D. A.
    Kropatcheva, E. S.
    Ignatiev, I. V.
    Bulytova, Yu. M.
    Dobrovolsky, A. B.
    Panchenko, E. P.
    Kukes, V. G.
    KARDIOLOGIYA, 2006, 46 (07) : 72 - 77
  • [28] Prevalence of Warfarin Genotype Polymorphisms in Patients with Mechanical Circulatory Support
    Awad, Morcos
    Czer, Lawrence S. C.
    Soliman, Camelia
    Mirocha, James
    Ruzza, Andrea
    Pinzas, Joshua
    Rihbany, Kelsey
    Chang, David
    Moriguchi, Jaime
    Ramzy, Danny
    Esmailian, Fardad
    Kobashigawa, Jon
    Arabia, Francisco
    ASAIO JOURNAL, 2015, 61 (04) : 391 - 396
  • [29] Warfarin dosing by genotype did not improve time in therapeutic range
    Dunn, Andrew
    ANNALS OF INTERNAL MEDICINE, 2014, 160 (06)
  • [30] EFFECT OF FACTOR-VII GENOTYPE ON RESPONSE TO WARFARIN TREATMENT
    LANE, A
    GREEN, F
    HUMPHRIES, S
    RUDDOCK, V
    MEADE, T
    THROMBOSIS AND HAEMOSTASIS, 1995, 73 (02) : 325 - 325
12345